Lilly’s Retatrutide Shows Breakthrough Weight Loss in Phase 3 TRIUMPH-1 Trial | iPharmaCenter
- Badari Andukuri
- 1 day ago
- 3 min read
Eli Lilly has reported strong top-line outcomes from its Phase 3 TRIUMPH-1 study, highlighting the significant weight reduction potential of its investigational obesity therapy, retatrutide. The once-weekly triple receptor agonist targets GIP, GLP-1, and glucagon pathways, positioning it as a next-generation metabolic treatment.
The late-stage trial evaluated adults living with obesity or overweight conditions accompanied by at least one related health complication, excluding individuals with diabetes. After 80 weeks of treatment, all tested dose levels met both primary and key secondary endpoints, demonstrating substantial and clinically meaningful reductions in body weight.
How effective is retatrutide for weight loss?
Patients receiving the highest dose of 12 mg achieved an average weight loss of 31.9 kg, corresponding to a 28.3% reduction from baseline. At this dose, nearly half of participants reached or exceeded 30% weight loss, a level typically associated with bariatric surgery outcomes.
The 9 mg dose resulted in an average reduction of 29.2 kg (25.9%), while the 4 mg dose led to a mean loss of 21.4 kg (19.0%), achieved with only a single dose escalation step.
Can retatrutide help patients move out of obesity classification?
A notable proportion of patients treated with 12 mg transitioned below the obesity threshold, achieving a body mass index under 30 by week 80. This included individuals who initially had severe obesity, indicating meaningful clinical improvement across high-risk populations.
Does weight loss continue beyond 80 weeks?
Extended data suggest continued benefits over time. In participants with a baseline BMI of 35 or higher who entered the extension phase, those maintained on treatment for 104 weeks experienced an average weight reduction of up to 38.5 kg, representing over 30% loss from baseline.
What additional health benefits were observed?
Beyond weight reduction, retatrutide demonstrated improvements in several cardiometabolic risk markers. These included reductions in waist circumference, triglycerides, non-HDL cholesterol, systolic blood pressure, and inflammatory markers such as high-sensitivity C-reactive protein.
What about safety and tolerability of retatrutide?
The safety profile of retatrutide was generally aligned with other incretin-based treatments. Adverse events were consistent with this drug class, and lower discontinuation rates were observed at the 4 mg dose compared to placebo, suggesting favorable tolerability at lower dosing levels.
What is retatrutide and how does it work?
Retatrutide is an experimental, once-weekly injectable therapy that simultaneously activates three key hormone receptors involved in metabolism: GIP, GLP-1, and glucagon. This multi-target mechanism is designed to enhance weight loss, improve metabolic health, and potentially address multiple obesity-related conditions.
The drug is currently under investigation across a broad Phase 3 development program, which includes studies in obesity, type 2 diabetes, obstructive sleep apnea, osteoarthritis pain, cardiovascular outcomes, and liver disease linked to metabolic dysfunction.
What is the TRIUMPH clinical program?
TRIUMPH-1 is part of a larger global clinical development initiative assessing retatrutide across multiple indications. The study enrolled over 2,300 participants who were randomized to receive one of three dose levels or placebo over an 80-week period. A subset of patients continued into a longer extension phase lasting up to 104 weeks.
The broader TRIUMPH program, launched in 2023, has recruited more than 5,800 participants worldwide. Additional trial results are expected to be released in the coming months, potentially shaping the future landscape of obesity treatment.
Comments